Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: J Urol. 2016 Oct 27;197(3 Pt 1):614–620. doi: 10.1016/j.juro.2016.10.067

Table 2.

Clinical characteristics by cohort

CEASAR PCOS p-value
PSA, ng/mL
 Median (Q1, Q3) 5.5 (4.3, 7.6) 7.5 (5.2, 11.9) <0.001
Clinical T-stage, % (n)
 T1 76 (2453) 32 (831) <0.001
 T2 24 (783) 44 (1164)
 T1 or T2 0 (0) 24 (630)
Biopsy Gleason score, % (n)
 6 or less 51 (1658) 66 (1734) <0.001
 7 38 (1236) 25 (669)
 8–10 11 (352) 8 (222)
Risk of recurrence, % (n)
 Low 44 (1426) 49 (1277) 0.004
 Intermediate 39 (1254) 35 (907)
 High 17 (558) 17 (441)

CEASAR - Comparative Effectiveness Analysis of Surgery and Radiation; PCOS - Prostate Cancer Outcomes Study; PSA - prostate specific antigen